219 related articles for article (PubMed ID: 34446937)
1. Prognostic value of blood cell count-derived ratios in BRAF-mutated metastatic melanoma.
Kopecky J; Kubecek O; Priester P; Vosmikova H; Cermakova E; Kyllarova A
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Dec; 166(4):393-404. PubMed ID: 34446937
[TBL] [Abstract][Full Text] [Related]
2. Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors.
Kahn AM; Perry CJ; Etts K; Kluger H; Sznol M
Oncologist; 2024 Apr; 29(4):e507-e513. PubMed ID: 37971411
[TBL] [Abstract][Full Text] [Related]
3. The outcome in patients with BRAF-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting.
Kopecký J; Pásek M; Lakomý R; Melichar B; Mrazová I; Kubeček O; Arenbergerová M; Lemstrová R; Švancarová A; Tretera V; Hlodáková A; Žváčková K
Cancer Med; 2024 Mar; 13(5):e6982. PubMed ID: 38491825
[TBL] [Abstract][Full Text] [Related]
4. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J
J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943
[TBL] [Abstract][Full Text] [Related]
5. Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma.
Reijers ILM; Rozeman EA; Wilgenhof S; van Thienen JV; Haanen JBAG; Blank CU
Pigment Cell Melanoma Res; 2020 May; 33(3):498-506. PubMed ID: 31646741
[TBL] [Abstract][Full Text] [Related]
6. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.
Czarnecka AM; Teterycz P; Mariuk-Jarema A; Lugowska I; Rogala P; Dudzisz-Sledz M; Switaj T; Rutkowski P
Target Oncol; 2019 Dec; 14(6):729-742. PubMed ID: 31754963
[TBL] [Abstract][Full Text] [Related]
7. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
Wagner NB; Lenders MM; Kühl K; Reinhardt L; Fuchß M; Ring N; Stäger R; Zellweger C; Ebel C; Kimeswenger S; Oellinger A; Amaral T; Forschner A; Leiter U; Klumpp B; Hoetzenecker W; Terheyden P; Mangana J; Loquai C; Cozzio A; Garbe C; Meier F; Eigentler TK; Flatz L
Eur J Cancer; 2024 Jan; 196():113425. PubMed ID: 38039778
[TBL] [Abstract][Full Text] [Related]
8. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of total metabolic tumour volume and therapy-response assessment by [
Annovazzi A; Ferraresi V; Rea S; Russillo M; Renna D; Carpano S; Sciuto R
Eur Radiol; 2022 May; 32(5):3398-3407. PubMed ID: 34779873
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG.
Zaremba A; Mohr P; Gutzmer R; Meier F; Pföhler C; Weichenthal M; Terheyden P; Forschner A; Leiter U; Ulrich J; Utikal J; Welzel J; Kaatz M; Gebhardt C; Herbst R; Sindrilaru A; Dippel E; Sachse M; Meiss F; Heinzerling L; Haferkamp S; Weishaupt C; Löffler H; Kreft S; Griewank K; Livingstone E; Schadendorf D; Ugurel S; Zimmer L
Eur J Cancer; 2023 Jul; 188():140-151. PubMed ID: 37245442
[TBL] [Abstract][Full Text] [Related]
11. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
Samlowski W; Adajar C
BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
[TBL] [Abstract][Full Text] [Related]
12. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
[TBL] [Abstract][Full Text] [Related]
13. The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.
Ma VT; Daignault-Newton S; Waninger JJ; Journey S; Chopra Z; Tezel A; Redman BG; Fecher LA; Green MD; Alva AS; Lao CD
Pigment Cell Melanoma Res; 2021 May; 34(3):629-640. PubMed ID: 33128316
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Clinical and Radiographic Biomarkers for BRAF-Targeted Therapy in Advanced Melanoma.
Shah KP; Song H; Ye F; Johnson DB
Oncologist; 2021 Feb; 26(2):e333-e335. PubMed ID: 33044751
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma.
Kiniwa Y; Okuyama R
Jpn J Clin Oncol; 2021 Mar; 51(3):315-320. PubMed ID: 33338202
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma.
Iacono D; Basile D; Gerratana L; Vitale MG; Pelizzari G; Cinausero M; Poletto E; Puglisi F; Fasola G; Minisini AM
Melanoma Res; 2019 Oct; 29(5):510-515. PubMed ID: 30702508
[TBL] [Abstract][Full Text] [Related]
17. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
Devji T; Levine O; Neupane B; Beyene J; Xie F
JAMA Oncol; 2017 Mar; 3(3):366-373. PubMed ID: 27787543
[TBL] [Abstract][Full Text] [Related]
18. Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma.
Guida M; Bartolomeo N; Quaresmini D; Quaglino P; Madonna G; Pigozzo J; Di Giacomo AM; Minisini AM; Tucci M; Spagnolo F; Occelli M; Ridolfi L; Queirolo P; De Risi I; Valente M; Sciacovelli AM; Chiarion Sileni V; Ascierto PA; Stigliano L; Strippoli S
J Transl Med; 2022 Apr; 20(1):159. PubMed ID: 35382857
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors.
Stadler JC; Keller L; Mess C; Bauer AT; Koett J; Geidel G; Heidrich I; Vidal-Y-Sy S; Andreas A; Stramaglia C; Sementsov M; Haberstroh W; Deitert B; Hoehne IL; Reschke R; Haalck T; Pantel K; Gebhardt C; Schneider SW
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258039
[TBL] [Abstract][Full Text] [Related]
20. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
